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INTERFERON ALFA-2b ALONE OR IN COMBINATION WITH RIBAVIRIN FOR THE
TREATMENT OF RELAPSE OF CHRONIC HEPATITIS C
GARY L. DAVIS, M.D., RAFAEL ESTEBAN-MUR, M.D., VINOD RUSTGI, M.D., JOHN HOEFS, M.D., STUART C. GORDON, M.D.,
CHRISTIAN TREPO, M.D., MITCHELL L. SHIFFMAN, M.D., STEFAN ZEUZEM, M.D., ANTONIO CRAXI, M.D.,
MEI-HSIU LING, PH.D., AND JANICE ALBRECHT, PH.D., FOR THE INTERNATIONAL HEPATITIS INTERVENTIONAL THERAPY GROUP*

ABSTRACT
Background Interferon alfa is the only effective
treatment for patients with chronic hepatitis C. Forty
percent of patients have an initial response to this
therapy, but most subsequently relapse. We compared the effect of interferon alone with that of interferon plus oral ribavirin for relapses of chronic hepatitis C.
Methods We studied 345 patients with chronic
hepatitis C who relapsed after interferon treatment.
A total of 173 patients were randomly assigned to receive standard-dose recombinant interferon alfa-2b
concurrently with ribavirin (1000 to 1200 mg orally
per day, depending on body weight) for six months,
and 172 patients were assigned to receive interferon
and placebo.
Results At the completion of treatment, serum
levels of hepatitis C virus (HCV) RNA were undetectable in 141 of the 173 patients who were treated with
interferon and ribavirin and in 80 of the 172 patients
who were treated with interferon alone (82 percent
vs. 47 percent, P<0.001). Serum HCV RNA levels remained undetectable 24 weeks after the end of treatment in 84 patients (49 percent) in the combinationtherapy group, but in only 8 patients (5 percent) in
the interferon group (P<0.001). Sustained normalization of serum alanine aminotransferase concentrations and histologic improvement were highly
correlated with virologic response. Base-line serum
HCV RNA levels of 2¬106 copies per milliliter or less
were associated with higher rates of response in
both treatment groups. Viral genotypes other than
type 1 were associated with sustained responses
only in the combination-therapy group. Combined
therapy caused a predictable fall in hemoglobin concentrations but otherwise had a safety profile similar
to that of interferon alone.
Conclusions In patients with chronic hepatitis C
who relapse after treatment with interferon, therapy
with interferon and oral ribavirin results in higher
rates of sustained virologic, biochemical, and histologic response than treatment with interferon alone.
(N Engl J Med 1998;339:1493-9.)
©1998, Massachusetts Medical Society.

N

EARLY 4 million people in the United
States and 100 million worldwide are infected with the hepatitis C virus (HCV).1
Of these, approximately 70 percent have
chronic hepatitis and 15 to 20 percent will eventually have cirrhosis.2-4 Chronic hepatitis C is the most
common cause of chronic liver disease and the leading indication for liver transplantation in the United
States.1,5
Interferon alfa is the only effective treatment for
chronic hepatitis C.6-9 In approximately 40 percent
of patients, serum alanine aminotransferase concentrations fall to normal and HCV RNA disappears
from serum during short courses of treatment, but
most patients relapse soon after stopping therapy.6-9
Although longer courses of treatment (12 to 24
months) increase the duration of the initial response,
many patients still relapse.10-13
Ribavirin is a synthetic nucleoside analogue with in
vitro activity against several viruses.14 Treatment with
ribavirin alone reduces serum alanine aminotransferase concentrations, but not serum HCV RNA levels,
in patients with chronic hepatitis C.15-17 Pilot studies
suggested that the combination of interferon and ribavirin reduced relapse, as compared with interferon
alone, thereby increasing the likelihood of a sustained
response.18-21 Furthermore, among eight patients who
relapsed after an initial response to interferon, six had
a sustained response to combination treatment.18 By
comparison, treatment of patients who relapse with
the same dose of interferon that was used initially
rarely results in a sustained response.22,23
The aim of this study was to compare the safety
and efficacy of recombinant interferon alfa-2b alone
and in combination with oral ribavirin for the treatment of patients with chronic hepatitis C who relapsed after a response to interferon therapy.
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(G.L.D.); Hospital Vall d’Hebron, Barcelona, Spain (R.E.-M.); Inova Institute of Research and Education, Falls Church, Va. (V.R.); University of
California at Irvine, Orange (J.H.); William Beaumont Hospital, Royal
Oak, Mich. (S.C.G.); Hôpital Hotel Dieu, Lyons, France (C.T.); Medical
College of Virginia, Richmond (M.L.S.); Klinikum der J.W. Goethe
Universität, Frankfurt, Germany (S.Z.); Policlinico P. Giaccone, Palermo,
Italy (A.C.); and Schering-Plough Research Institute, Kenilworth, N.J.
(M.-H.L., J.A.). Address reprint requests to Dr. Davis at the Section of
Hepatobiliary Diseases, Box 100214, University of Florida College of Medicine, Gainesville, FL 32610-0214.
*The other members of the International Hepatitis Interventional Therapy Group are listed in the Appendix.
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METHODS
Patients
Adult patients with chronic hepatitis C who had previously received one or two courses of recombinant or lymphoblastoid interferon alfa (interferon alfa-2b [Intron A], Schering-Plough,
Kenilworth, N.J.; interferon alfa-2a [Roferon-A], Hoffmann–La
Roche, Nutley, N.J.; or interferon alfa-n1 [Wellferon], Glaxo
Wellcome, Research Triangle Park, N.C.) at a dose of 3 million
to 6 million units three times per week for at least 20 weeks but
not more than 18 months without a reduction in the dose or an
interruption in treatment were eligible for the study. The patients
had to have had a response to the most recent course of interferon — defined as a normal serum alanine aminotransferase concentration at the end of therapy — followed by a relapse, with an
elevation in serum alanine aminotransferase concentrations, within one year after treatment was stopped. All patients also had to
have undergone a liver biopsy showing chronic hepatitis after they
had relapsed and within six months before enrollment. All women in the study were required to use effective birth control. The
following were reasons for exclusion: decompensated cirrhosis,6 a
hemoglobin concentration of less than 12 g per deciliter in women and less than 13 g per deciliter in men, a white-cell count of
less than 3000 per cubic millimeter, a neutrophil count of less
than 1500 per cubic millimeter, a platelet count of less than
100,000 per cubic millimeter, human immunodeficiency virus infection, prior organ transplantation, severe psychiatric conditions,
a seizure disorder, cardiovascular disease, renal insufficiency, hemoglobinopathy, hemophilia, poorly controlled diabetes mellitus,
and immunologically mediated diseases.
Study Design and Treatment Regimens
The study was a double-blind, placebo-controlled trial conducted in the United States and internationally. The patients were
randomly assigned to treatment by a centralized computer algorithm that stratified enrollment according to the presence of cirrhosis, high serum HCV RNA levels, and HCV genotype 1 — all
of which reduce the response to interferon.24,25 The treatments
consisted of 24 weeks of subcutaneous interferon alfa-2b at a
dose of 3 million units three times per week plus either oral ribavirin (Rebetron, Schering-Plough), administered twice daily at a
total daily dose of 1000 mg (for patients who weighed 75 kg or
less) or 1200 mg (for those who weighed more than 75 kg), or
a matched placebo.
A total of 495 patients were screened, of whom 349 met the
entry criteria and were assigned to a treatment group. Four patients withdrew before receiving treatment. Therefore, 173 patients received interferon and ribavirin (77 in the United States
and 96 at international sites), and 172 patients received interferon
and placebo (76 in the United States and 96 at international
sites). The patients were evaluated after 1, 2, 4, 6, and 8 weeks of
treatment and then monthly thereafter and 4, 8, 12, and 24 weeks
after treatment was discontinued.
All biochemical and hematologic tests were performed in central laboratories. Serum was collected and stored under conditions known to optimize the detection of HCV RNA. 26 Serum
HCV RNA was measured before treatment, at the end of treatment, and at the last follow-up visit by a quantitative reverse-transcription–polymerase-chain-reaction assay with a lower limit of
detection of 100 copies per milliliter (National Genetics Institute,
Culver City, Calif.). A liver biopsy was performed at the end of
the follow-up period.
The study was conducted between April 1996 and July 1997.
The protocol was approved by the institutional review committee
at each site, and all patients provided written informed consent.
End Points
The primary end points were the disappearance of HCV RNA
from serum and histologic improvement at the end of the 24week follow-up period. In patients who have undetectable serum
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HCV RNA levels for 24 weeks after treatment, the concentrations remain undetectable indefinitely.27 For consistency with
other reports and current clinical practice, we also reported conventional end points as defined by the National Institutes of
Health Consensus Development Conference on Hepatitis C. 28
These include a response at the end of treatment (defined as normal serum alanine aminotransferase concentrations and undetectable serum HCV RNA levels at the end of therapy) and a sustained response (defined as a response that persists for at least six
months after treatment).
Liver-biopsy specimens obtained before treatment and at the
end of the follow-up period were interpreted by a single pathologist who was unaware of the patients’ treatment assignment or
the timing of the biopsy. The degree of hepatic inflammation and
fibrosis was scored with the Knodell Histologic Activity Index 29
and the Metavir system,30 respectively. The inflammation score
was obtained by combining the scores for the first three components of the Knodell index (portal, periportal, and lobular inflammation). The scores can range from 0 to 18, and higher scores
indicate more severe abnormalities. Histologic improvement was
defined as a decrease in the inflammation score of at least two
points. Fibrosis was graded according to the Metavir system, in
which a score of 0 indicates the absence of fibrosis and a score of
4 indicates cirrhosis.
Statistical Analysis
The analysis was based on the 345 patients who received treatment. The demographic information, viral characteristics, and
treatment responses for the U.S. patients and the patients at international sites were nearly identical, and the data were therefore
combined. The base-line characteristics of the treatment groups
were compared with use of the chi-square test or the Wilcoxon
rank-sum test.31 Treatment responses were compared with use of
the Cochran–Mantel–Haenszel test or analysis of variance (for
liver-biopsy specimens).31 The relatedness of various pretreatment
characteristics to the response was examined with use of stepwise
logistic-regression analysis.31 All statistical tests were two-tailed.

RESULTS
Characteristics of the Patients

The two treatment groups were well matched (Table 1). Most patients had previously received a single
course of interferon alfa-2b that lasted less than 12
months. The pretreatment serum HCV RNA levels,
the percentage of patients with HCV genotype 1,
and the numbers of patients with fibrosis and cirrhosis were similar in the two groups. The proportions
with HCV genotype 1 or cirrhosis were lower than
in most trials of previously untreated patients with
chronic hepatitis C, because patients with these characteristics are less likely to have an initial response to
interferon therapy and therefore would not have had
the opportunity to relapse and qualify for this study.
Serum HCV RNA

Serum HCV RNA levels became undetectable by
the end of treatment in 141 of the 173 patients (82
percent) who were treated with interferon and ribavirin and in 80 of the 172 patients (47 percent) who
were treated with interferon alone (P<0.001). Among
the patients in whom serum levels of HCV RNA
were undetectable at the end of treatment, the levels
became undetectable during the first four weeks of
treatment in 124 of the 141 patients (88 percent) in
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TABLE 1. BASE-LINE CHARACTERISTICS

OF THE

PATIENTS.*

INTERFERON
(N=172)

CHARACTERISTIC

Male sex — no. (%)
Age — yr
Mean
Range
White race — no. (%)
Weight — kg
Estimated duration of infection — yr†
Mean
Range
Source of infection — no. (%)
Transfusion
Injection-drug use
Unknown
Genotype — no. (%)
1
2
3
Mixed or other
Serum HCV RNA
No. of copies/ml
>2¬106 copies/ml — no. (%)
Bridging fibrosis — no. (%)
Cirrhosis — no. (%)
Fibrosis score‡
Knodell score§
Serum alanine aminotransferase —
no. of times upper limit of normal
Mean
Range
Previous therapy
Interferon alfa-2b — no. (%)
Single course — no. (%)
<12 mo in duration — no. (%)
Median duration — days
Time from end of last treatment to
enrollment — no. (%)
«12 mo
13–24 mo
>24 mo

INTERFERON
RIBAVIRIN
(N=173)

AND

112 (65)

112 (65)

42
26–76
158 (92)
74.7±13.3

44
23–69
165 (95)
75.6±15.1

16±8
1.5–38

15±8
1.4–38

than in those with a later response (87 percent vs. 59
percent in the combination-therapy group, 42 percent vs. 10 percent in the interferon group). In all
patients who had sustained responses, serum HCV
RNA levels became undetectable before 12 weeks of
treatment.
Serum Alanine Aminotransferase

52 (30)
68 (40)
52 (30)

42 (24)
70 (40)
61 (35)

94
34
39
5

98
25
46
4

(55)
(20)
(23)
(3)

(57)
(14)
(27)
(2)

5.2¬106
131 (76)
29 (17)
6 (3)
1.3±0.7
6.8±2.6

4.8¬106
128 (74)
23 (13)
3 (2)
1.2±0.6
6.7±2.6

3.0±1.9
1.0–11.2

3.2±2.1
1.0–13.9

118 (69)
154 (90)
149 (87)
190

131 (76)
161 (93)
153 (88)
185

63 (37)
69 (40)
40 (23)

75 (43)
48 (28)
50 (29)

*Plus–minus values are means ±SD. There were no significant differences between the two groups. Because of rounding, percentages may not total 100.
†The duration of infection was estimated from the date of transfusion or
first exposure.
‡Scores could range from 0 to 4, with a score of 4 indicating cirrhosis.
§Scores could range from 0 to 18, with higher scores indicating more
severe abnormalities.

Serum alanine aminotransferase concentrations
were normal by the end of treatment in 154 of the
173 patients (89 percent) in the combination-therapy group and in 98 of the 172 patients (57 percent)
in the interferon group (P<0.001). Among the patients with such a response, those treated with combination therapy were more likely to have undetectable serum HCV RNA levels than those treated with
interferon alone (85 percent vs. 70 percent, P=
0.007). The serum alanine aminotransferase concentrations remained normal throughout follow-up in
81 patients (47 percent) in the combination-therapy
group, as compared with only 8 patients (5 percent)
in the interferon group (P<0.001).
Discrepancies between the serum HCV RNA responses and the alanine aminotransferase responses
to interferon therapy have been reported.32 In this
study, serum HCV RNA levels remained detectable
after treatment despite persistently normal serum
alanine aminotransferase concentrations in 10 of 89
patients (11 percent) in the combination-therapy
group and in 18 of 164 patients (11 percent) in the
interferon group. In contrast, all but three patients
in whom serum HCV RNA levels became undetectable had normal serum alanine aminotransferase concentrations.
Traditional Treatment End Points

When we assessed conventional end points defined according to the National Institutes of Health
Consensus Development Conference,28 we found that
133 patients (77 percent) in the combination-therapy group had a response at the end of treatment, as
compared with 69 patients (40 percent) in the interferon group. The rates of sustained response were 47
percent (81 patients) and 5 percent (8 patients), respectively.
Histologic Analysis

the combination-therapy group and in 44 of the 80
patients (55 percent) in the interferon group.
Serum HCV RNA levels remained undetectable
throughout the follow-up period (defined as a sustained virologic response) in 84 patients (49 percent)
in the combination-therapy group, but in only 8 patients (5 percent) in the interferon group (P<0.001).
The response was more likely to be sustained in patients in whom serum HCV RNA levels became undetectable during the first four weeks of treatment

Pretreatment and post-treatment liver-biopsy specimens were available from 277 patients. Forty-eight
patients refused to undergo or did not return for a
second biopsy, 14 had inadequate biopsy specimens,
the tissue blocks were lost in the case of 3 patients,
a post-treatment biopsy was considered unsafe in the
case of 2 patients, and 1 patient died.
Histologic improvement occurred in both treatment groups, but it was more common in the group
treated with interferon and ribavirin (87 of 139 patients, 63 percent) than in the group treated with inVol ume 33 9
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TABLE 2. RATES OF SUSTAINED RESPONSE TO TREATMENT
ACCORDING TO THE HCV GENOTYPE, BASE-LINE SERUM
HCV RNA LEVEL, AND THE PRESENCE OF FIBROSIS OR CIRRHOSIS
ON LIVER BIOPSY AT BASE LINE.

CHARACTERISTIC

INTERFERON
RIBAVIRIN*

INTERFERON

AND

no./total no. of patients (%)

Genotype
1
Other
Base-line HCV RNA level
>2¬106 copies/ml
«2¬106 copies/ml
Degree of fibrosis at base line
Fibrosis or cirrhosis¶
Minimal or no fibrosis

3/94 (3)
5/78 (6)

29/98 (30)†
55/75 (73)

2/131 (2)‡
6/41 (15)

54/128 (42)§
30/45 (67)

1/35 (3)
6/134 (4)

12/26 (46)
70/142 (49)

*P<0.001 for the comparison with interferon alone for each characteristic tested.
†P<0.001 for the comparison with the other genotypes.
‡P=0.003 for the comparison with a serum HCV RNA level of
«2¬106 copies per milliliter.
§P=0.006 for the comparison with a serum HCV RNA level of
«2¬106 copies per milliliter.
¶Septal fibrosis was defined by a Metavir score of 2 or 3, and cirrhosis
by a score of 4. Liver-biopsy specimens were insufficient for analysis in the
case of three patients in the interferon group and five patients in the combination-therapy group.

TABLE 3. RELATION OF VIRAL GENOTYPE AND
BASE-LINE SERUM HCV RNA LEVEL TO THE
RESPONSE TO TREATMENT.
GENOTYPE AND
HCV RNA LEVEL

INTERFERON

INTERFERON
RIBAVIRIN*

AND

no./total no. of patients (%)

Genotype other than
type 1
«2¬106 copies/ml
>2¬106 copies/ml
Genotype 1
«2¬106 copies/ml
>2¬106 copies/ml

Correlation of Base-Line Characteristics with Response

The HCV genotype, pretreatment serum HCV
RNA levels, and the presence of fibrosis or cirrhosis
at base line influence the initial response to treatment with interferon alone.25,33,34 Patients who were
treated with combination therapy were more likely
to have a sustained response regardless of the genotype, serum HCV RNA levels at base line, or histologic findings at base line (Table 2). However, in this
group, a sustained viral response was more common
in patients with serum HCV RNA levels of 2¬106
copies per milliliter or less (P=0.006) or HCV genotypes other than type 1 (P<0.001). The combination of the viral genotype and the pretreatment serum HCV RNA level was significantly associated
with a response to combination therapy (Table 3).
In contrast, in patients who were treated with interferon alone, a sustained loss of serum HCV RNA
was more common in those with pretreatment serum HCV RNA levels of 2¬106 copies per milliliter
or less (P=0.003), but it was not significantly influenced by the HCV genotype. The rate of response
to either treatment was not influenced by the presence of fibrosis or cirrhosis at base line, age, sex,
body weight, the presumed source of infection, or
the type, dose, and duration of prior interferon
treatment.
Adverse Events

3/17 (18)
2/61 (3)

20/20 (100)†‡
36/55 (65)§

3/24 (12)¶
0/70

10/25 (40)
18/73 (25)

*P<0.001 for the comparison with interferon alone for
each characteristic.
†P<0.002 for the comparison with a genotype other than
type 1 with serum HCV RNA levels of more than 2¬106
copies per milliliter.
‡P<0.001 for the comparison with genotype 1 with serum HCV RNA levels of «2¬106 copies per milliliter.
§P<0.05 for the comparison with genotype 1 with serum
HCV RNA levels of more than 2¬106 copies per milliliter.
¶P=0.02 for the comparison with genotype 1 with serum
HCV RNA levels of more than 2¬106 copies per milliliter.
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terferon alone (57 of 138 patients, 41 percent; P<
0.001). The mean decreases in the inflammatory
scores were 2.6 and 0.7, respectively (P<0.001). Histologic improvement was strongly associated with a
sustained loss of serum HCV RNA regardless of the
treatment (P<0.001). Among patients in whom serum HCV RNA levels remained detectable, the
mean decline in the levels was similar in those with
histologic improvement and those without histologic improvement.

Ribavirin accumulates in red cells and results in
hemolysis.17 The mean (±SE) hemoglobin concentration in the combination-therapy group fell from
14.4±1.2 to 12.4±1.4 g per deciliter during the first
month of treatment, remained stable thereafter, and
returned to values that were close to base-line values
within four weeks after treatment was stopped. The
values fell below 11.0 g per deciliter in 43 patients
(25 percent) and below 10.0 g per deciliter in 15 patients (9 percent). The decline was accompanied by
reticulocytosis (reticulocytes, 2.8±0.1 percent). Fifteen patients (9 percent) had a serum total bilirubin
concentration of more than 2 mg per deciliter (34
µmol per liter), and 42 patients (24 percent) had a
high serum uric acid concentration. In the interferon group, the mean hemoglobin concentration decreased by 0.8±0.7 g per deciliter.
Both groups had similar decreases in the white-

Novem b er 19 , 19 9 8
The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 20, 2015. For personal use only. No other uses without permission.
Copyright © 1998 Massachusetts Medical Society. All rights reserved.

I N T E R F E R O N A L FA - 2 b A L O N E O R W I T H R I BAV I R I N F O R T H E T R E AT M E N T O F R E L A P S E O F C H R O N I C H E PAT I T I S C

cell count (35 percent in the combination-therapy
group and 23 percent in the interferon group) and
neutrophil count (33 percent and 28 percent, respectively), with a nadir after four weeks of treatment and recovery within four weeks after treatment
was stopped. The platelet counts also fell in both
groups, but the decrease was smaller in the combination-therapy group than in the interferon group
(7 percent vs. 15 percent).
Most patients had some symptoms during treatment (Table 4), but only nausea, dyspnea, and rash
were significantly more common in the combination-therapy group than in the interferon group.
The frequencies and types of other symptoms were
similar to those reported in patients who were treated with interferon alone.35 Other than depression,
no patient had any serious or potentially life-threatening complications, and there were no drug-related
deaths. One woman in the interferon group who
had a history of alcohol and injection-drug abuse
committed suicide three months after treatment was
stopped. She had not reported depression during interferon treatment. No other patient died, and none
required liver transplantation.
The dose of interferon or ribavirin was reduced or
treatment was discontinued for at least three days in
20 patients (12 percent) in the combination-therapy
group, mostly because of anemia (12 patients), and in
5 patients (3 percent) in the interferon group. Treatment was discontinued in 10 patients (6 percent) in
the combination-therapy group and in 5 (3 percent)
in the interferon group. The reasons for discontinuation in the combination-therapy group included
depression (five patients), neutropenia (two patients),
hyperthyroidism with tachycardia (one patient), arthralgia (one patient), and cough (one patient); the
reasons for discontinuation in the interferon group
were suicidal ideation, nausea, dehydration, insomnia, and musculoskeletal pain (one patient each).
DISCUSSION

In approximately 40 percent of patients with
chronic hepatitis C, interferon therapy results in normalization of serum alanine aminotransferase concentrations, loss of detectable HCV RNA in serum,
and histologic improvement, but the majority relapse shortly after treatment is stopped.6,8-10,36 Many
but not all of these patients have a response to a second course of treatment, but sustained responses are
uncommon.6,22,37-39 A second course of treatment
with higher doses than the first course or for longer
periods or both leads to sustained responses in 20
to 50 percent of patients,22,37-40 but these regimens
are costly and poorly tolerated.
Our study confirms that after relapse, the results
of treatment with the same dose of interferon that
was used initially are disappointing. In contrast,
however, treatment after relapse with a combination

TABLE 4. RATES

OF

SYMPTOMS

DURING

INTERFERON
(N=172)

SYMPTOM

TREATMENT.*
INTERFERON
RIBAVIRIN
(N=173)

AND

percent

Influenza-like symptoms
Headache
Fatigue or asthenia
Myalgia
Arthralgia
Fever
Rigors
Gastrointestinal symptoms
Anorexia
Nausea
Diarrhea
Psychiatric symptoms
Depression
Insomnia
Respiratory tract symptoms
Cough
Dyspnea
Pharyngitis
Dermatologic symptoms
Alopecia
Rash
Pruritus

54
39
39
23
33
21

55
46
44
21
32
26

13
20
18

20
35†
12

11
23

16
20

9
6
9

10
14‡
11

18
5
6

21
13‡
13

*Only symptoms that occurred in at least 10 percent of all
patients were included.
†P=0.002 for the comparison with interferon alone.
‡P=0.02 for the comparison with interferon alone.

of interferon and ribavirin for just six months resulted in sustained loss of HCV RNA from serum in
nearly half the patients, most of whom had histologic improvement.
The likelihood of a favorable response to treatment with either regimen after relapse was related to
the pretreatment serum HCV RNA level. The results of previous studies of the importance of changes in HCV RNA levels with respect to the response
to treatment with interferon after relapse are conflicting,37,41,42 possibly because of differences in the
method of serum collection,26 the HCV RNA assay,43 or the viral response to the first course of treatment. Patients in whom serum alanine aminotransferase concentrations return to normal and serum
HCV RNA levels become undetectable during the
first course of interferon are more likely to have a response to treatment after relapse than those in
whom serum alanine aminotransferase values return
to normal but viremia persists.22 We do not know
what proportion of our patients were seronegative
for HCV RNA after their earlier course of interferon, because most had been treated in communities
where these assays were not widely available.
The HCV genotype was strongly associated with
the response to combination therapy. The genotype
and the pretreatment serum HCV RNA level also
Vol ume 33 9
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appeared to be related, with rates of responses as
high as 100 percent in patients with low serum HCV
RNA levels at base line and a genotype other than
type 1. In contrast to previous reports,22 our data
suggest that the HCV genotype has no influence on
the response to treatment with interferon alone after
relapse.
Both treatment regimens were safe and reasonably
well tolerated. The only important risk associated
with combination therapy was hemolytic anemia, as
previously noted in trials of ribavirin alone.17 The fall
in the hemoglobin concentration occurred during
the first month of treatment and was sometimes
substantial, thus emphasizing the need for careful
monitoring of patients during treatment with ribavirin.
In summary, the combination of interferon and
ribavirin is safe and effective for the treatment of patients with chronic hepatitis C who relapse after an
initial response to therapy with interferon alone.
Combination therapy offers a striking advantage
over interferon monotherapy: it had a much higher
rate of sustained response. Although treatment lasted only six months in our study, our results with
combination therapy are as good as or better than
those in patients who were treated with higher doses
and longer courses of interferon.22,40 Furthermore,
treatment with combination therapy after relapse
frequently resulted in histologic improvement. The
reduction in hepatic inflammation was most striking
in patients in whom serum HCV RNA levels became persistently undetectable, and on the basis of
previous observations, we would expect this effect to
persist and to grow over time.27,44 Finally, our results
emphasize that a response to an initial course of interferon does not guarantee a response after relapse,
even with the use of a combination of interferon and
ribavirin. Thus, every effort should be made in clinical practice and future trials to optimize the response to the first course of treatment. Currently,
the best treatment option is to administer interferon
for at least 12 months to patients in whom serum
alanine aminotransferase concentrations or serum
HCV RNA levels decrease soon after treatment is
started.45
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